West Pharmaceutical Q4 net sales rise 7.5%, beat estimates

West Pharmaceutical Services

12/02/2026 11:10

Overview

Injectable solutions provider's Q4 net sales rose 7.5%, beating analyst expectations

Adjusted EPS for Q4 beat consensus, driven by HVP Components growth

Company repurchased 552,593 shares for $134 mln during 2025

Outlook

West Pharmaceutical expects full-year 2026 net sales between $3.215 bln and $3.275 bln

Company projects full-year 2026 adjusted-diluted EPS between $7.85 and $8.20

First-quarter 2026 net sales expected between $770 mln and $790 mln

Result Drivers

HVP COMPONENTS - Strong Q4 performance driven by 20.3% increase in HVP Components sales, supported by Westar and Envision products

CONTRACT-MANUFACTURED PRODUCTS - Growth in self-injection devices for obesity and diabetes boosted segment sales by 6.2%

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net sales
Beat
$805 mln
$794.38 mln (11 Analysts)
Q4 Adjusted EPS
Beat
$2.04
$1.83 (13 Analysts)
Q4 EPS
$1.82


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for West Pharmaceutical Services Inc is $343.50, about 39.5% above its February 11 closing price of $246.16

The stock recently traded at 32 times the next 12-month earnings vs. a P/E of 37 three months ago

Press Release: ID:nPn3nLyvGa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)